BioAge Labs Inc. Stock Price, News & Analysis

BioArctic AB (Nasdaq Stockholm: BIOA B) announced that its partner Eisai has received the 9th Bioindustry Award from the Japan Bioindustry Association for the drug discovery research of lecanemab (Leqembi®), an antibody treatment for early Alzheimer's disease.

The treatment, co-developed by BioArctic and Eisai, is based on Professor Lars Lannfelt's discoveries about amyloid-beta protein's role in Alzheimer's disease. Lecanemab works by binding to specific forms of amyloid-beta and helping clear it from the brain. Eisai leads the global development and regulatory submissions, with both Eisai and Biogen handling commercialization. BioArctic retains commercialization rights in the Nordic region in partnership with Eisai.

BioArctic (NASDAQ Stockholm: BIOA B) announced that its founder, Professor Lars Lannfelt, will receive the prestigious 2025 Hartwig Piepenbrock-DZNE Prize for his pioneering work in Alzheimer's disease research and the development of lecanemab.

Professor Lannfelt, who founded BioArctic in 2003 with Pär Gellerfors, made groundbreaking discoveries about the role of amyloid-beta protein in Alzheimer's disease. These findings led to the development of lecanemab, an antibody treatment that targets specific forms of amyloid-beta in the brain, developed in collaboration with Eisai. The treatment showed positive results in the global Phase 3 Clarity AD trial.

The award ceremony will take place in Bonn in November 2025. The prize, awarded biennially since 2011, recognizes outstanding research in neurodegenerative disorders.

BioAge Labs (NASDAQ: BIOA) announced new preclinical data presentation at ADA's 85th Scientific Sessions regarding their APJ agonist treatment for diabetic obesity and heart failure. The data shows that APJ activation, combined with incretin therapy, demonstrated significant benefits in preclinical models. Key findings include improved glycemic control with a 25% enhancement in glucose tolerance and reduced HbA1c levels in diabetic obesity models. In heart failure models, the treatment showed cardioprotective effects and reduced cardiac hypertrophy. The company is developing both oral and injectable APJ agonist formulations, targeting an IND filing for 2026. The research suggests APJ agonists could act as exercise mimetics, potentially doubling the weight loss effects of GLP-1 receptor agonists while improving body composition and muscle function.

BioAge Labs (NASDAQ: BIOA) has announced a major expansion of its drug discovery platform through a collaboration with Norwegian diagnostics company Age Labs AS to analyze samples from the HUNT Biobank. The company will profile over 17,000 samples from 6,000+ participants, generating millions of molecular measurements to enhance their proprietary human aging data platform. The analysis will focus on participants who developed cardiometabolic disease (>50%) and cognitive decline/dementia (>35%), using Standard BioTools' SomaScan assay to quantify thousands of proteins per sample. This initiative will complement BioAge's existing platform that contains over 50 million molecular measurements collected across five decades, with exclusive drug discovery rights to the partnership-generated data.

BioArctic announced positive interim safety results for exidavnemab in its Phase 2a EXIST study, enabling progression to higher dose cohorts. The study evaluates exidavnemab as a potential disease-modifying treatment for Parkinson's disease and Multiple System Atrophy (MSA). The first cohort demonstrated that the lower dose was safe and well-tolerated compared to placebo in Parkinson's patients. Two new cohorts will now evaluate higher doses in both Parkinson's and MSA patients. Exidavnemab, a monoclonal antibody, selectively targets pathological alpha-synuclein aggregates while preserving physiological forms. The drug has received orphan drug designation in the US and a positive opinion for orphan medicinal product designation in the EU for MSA treatment. The EXIST study is randomized, double-blinded, and placebo-controlled, evaluating safety, tolerability, pharmacokinetics, and various biomarkers.

BioAge Labs has expanded its APJ agonist pipeline through two significant developments. First, the company entered an option agreement with JiKang Therapeutics to potentially in-license a novel APJ agonist nanobody that is 10-fold more potent than natural apelin. Second, BioAge filed a patent for new orally active small molecule APJ agonists with picomolar potency. The company's preclinical studies show that APJ agonism can double the weight loss effects of GLP-1 receptor agonists while improving muscle function and body composition. BioAge plans to advance both oral and subcutaneous APJ agonists for obesity treatment, targeting an IND filing in 2026. The JiKang agreement includes upfront payments, research funding, and potential milestone payments, while BioAge's internal small molecule program leverages computational modeling and AI design for drug development.

BioArctic AB (NASDAQ: BIOA B) hosted its Capital Markets Day 2025, outlining ambitious plans to become Sweden's next major pharmaceutical company by 2030. The company's strategy focuses on expanding its pipeline across brain diseases, securing global partnerships, and establishing Leqembi® for Alzheimer's treatment in the Nordic region. Key presentations covered financial outlook, with expected profitability from 2025, R&D strategy featuring their BrainTransporter™ technology enabling up to 70x greater brain exposure for antibodies, and updates on Leqembi® and exidavnemab programs. The event highlighted BioArctic's commitment to innovation in neurology, particularly their progress in Alzheimer's treatment and development of therapies for alpha-synuclein diseases including Parkinson's, Multiple System Atrophy, and Lewy body dementia.

BioAge Labs has completed IND-enabling studies for BGE-102, a novel oral NLRP3 inhibitor targeting obesity treatment. The compound demonstrated significant results in preclinical studies, achieving 15% weight reduction as monotherapy and over 20% weight reduction when combined with semaglutide. BGE-102 features high potency (2 nM IC90 in human microglia), brain penetration, and favorable safety profile, supporting once-daily dosing of less than 50 mg. The company plans to submit an IND application in mid-2025, with Phase 1 SAD data expected by year-end and a Phase 1b proof-of-concept obesity study planned for H2 2026. The drug's unique mechanism targets NLRP3, which BioAge identified as linked to longevity through analysis of human aging cohorts.

BioAge Labs (NASDAQ: BIOA), a clinical-stage biotech company focused on developing therapeutics for metabolic diseases through aging biology, has announced its participation in two major upcoming investor conferences. The company's leadership, including CEO and co-founder Dr. Kristen Fortney and CFO Dr. Dov Goldstein, will attend:

• The Jefferies Global Healthcare Conference in New York (June 3-5, 2025) for one-on-one meetings

• The Goldman Sachs 46th Annual Global Healthcare Conference in Miami (June 9-11, 2025), featuring a fireside chat on June 9 at 3:20 PM EDT and one-on-one meetings. A webcast will be available and archived for 30 days on the company's investor relations website.